INBPOTCPharmaceutical PreparationsFiscal year ends June 30
INTEGRATED BIOPHARMA INC
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 25, 2026
$0.18+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $5.59M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.1300 (−41.94%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
INTEGRATED BIOPHARMA INC saw revenue fall 19.3% to $43.87M over the twelve months to Jun 30, 2026. Operating income fell 233.9% to -$2.71M, moving the operating margin from 3.7% to -6.2%. Free cash flow was $895.00K, down 52.2% from a year earlier.
Revenue
$43.87M
-19.3% vs. a year earlier
Operating income
-$2.71M
-233.9% vs. a year earlier
Free cash flow
$895.00K
-52.2% vs. a year earlier
EPS, diluted
-$0.09
-400.0% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $5.59M
- P/E ratio
- –
- Price to sales
- 0.13
- Price to book
- 0.32
- Dividend yield
- –
- Free cash flow yield
- 16.01%
Fundamentals
- Revenue
- $43.87M
- Net income
- -$2.84M
- EPS, diluted
- -$0.09
- Free cash flow
- $895.00K
- Book value per share
- $0.57
- Diluted shares
- 31M
Fifteen years at a glance
Fiscal years 2012 to 2026, USD
Revenue
$43.87M-19.3% YoY
Gross profit
$800.00K-85.6% YoY
Operating income
-$2.71M-233.9% YoY
Net income
-$2.84M-451.7% YoY
EPS, diluted
-$0.09-400.0% YoY
Free cash flow
$895.00K-52.2% YoY
Reported period